Liberty vs Idgie Health
Two sellers that each volunteer something most of the category does not.
Liberty
Editorial
$199/mo
Liberty prices compounded semaglutide at a flat $199 a month and compounded tirzepatide at a flat $299, and states that both are sourced from a 503B outsourcing facility after a clinician review. A three-month supply brings the semaglutide to about $171 a month. A 503B registers with the FDA and compounds under current good manufacturing practice, which is not the same as approval.
Pick it for: Readers who want the compounding source named before ordering
Idgie Health
Editorial
$134/mo
Idgie Health prices a compounded semaglutide microdose at $134 a month, a tirzepatide microdose at $179, and an orally dissolving semaglutide tablet at $287. Three-month purchases are charged in full at $377, $497 and $747. The product copy describes microdosing as an off-label approach, which few sellers print beside a price.
Pick it for: Readers who want the regulatory position spelled out
Our verdict
Liberty names the 503B facility its medication comes from. Idgie Health states the off-label position plainly. Different disclosures, and both are rarer than the prices beside them.
What actually separates them
Liberty and Idgie Health state different things about published price. Everything else they publish, they publish the same way.
Liberty costs $65 more than Idgie Health — 49% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,608 at Idgie Health against $2,388 at Liberty — a difference of $780.
| Liberty | Idgie Health | |
|---|---|---|
| Published price | $199/mo | $134/mo |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.